Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.40 |
| ▸ | HTR3A | P46098 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.33 |
| ▸ | HTR3B | O95264 | 3/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731410 | 0.88 | MAPT (0.36) | ALDH1A1 | |
| SCHEMBL31372447 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CYP1A2ALOX15HSD17B10 | |
| SCHEMBL12731668 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CYP1A2ALOX15HSD17B10 | |
| SCHEMBL24894908 | 0.83 | MAPT (0.32) | HRH3 | |
| SCHEMBL19867589 | 0.83 | MAPT (0.43) | HRH3ALDH1A1ALOX15 | |
| SCHEMBL10169023 | 0.81 | HRH4 (0.35) | HRH4HTR3AHRH3METALDH1A1 | |
| SCHEMBL10137347 | 0.78 | HRH4 (0.39) | HRH4HTR3AHRH3HTR3EHTR3B | |
| SCHEMBL578540 | 0.78 | HTR3A (0.42) | HRH4HTR3AHRH3HTR3EHTR3B | |
| SCHEMBL29542633 | 0.78 | HTR3A (0.42) | HRH4HTR3AHRH3HTR3EHTR3B | |
| SCHEMBL25473799 | 0.78 | LRRK2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2906537-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10092572-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| WO-2014062733-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | HRH4 911/4885HTR3A 2158/4885HRH3 1485/4885 |
| US-10092572-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | HRH4 911/4885HTR3A 2158/4885HRH3 1485/4885 |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | HRH4 911/4885HTR3A 2158/4885HRH3 1485/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | HRH4 911/4885HTR3A 2158/4885HRH3 1485/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | HRH4 4420/4885HTR3A 4233/4885HRH3 4273/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | HRH4 4420/4885HTR3A 4233/4885HRH3 4273/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | HRH4 911/4885HTR3A 2158/4885HRH3 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.